Dr. Taneisha McFarlane the founder and CEO of HistoCare BioScience, is an accomplished oncology researcher with extensive clinical and research experience in cellular pathology and materials engineering. Her firsthand exposure to challenges such as the use of toxic chemicals, slow histology turnaround times, and the limited availability of diverse analyte control FFPE tissues she understands the frustrations faced by clinicians, biomedical scientists, and researchers and founded HistoCare to enhance efficiency, accuracy, and sustainability in histology.
A passionate advocate for sustainability, she leads initiatives to integrate environmentally responsible practices into healthcare and scientific research. Dr. McFarlane is committed to reducing the use of toxic chemicals, and has spearheaded efforts to replace these harmful substances with environmentally friendly alternatives, and setting new standards for responsible innovation in the healthcare industry.
She has developed innovative solutions to streamline research, improve turnaround times, and deliver a comprehensive range of high-quality FFPE controls to the life sciences and diagnostic industries supporting breakthroughs in cancer research and patient care.